Saturday 17 October 2026
Export PHIO’s income statement to Excel — free account
Phio Pharmaceuticals Corp.
PHIO Healthcare Biotechnology
In the quarter to June 2026, EPS grew 20.0% and free cash flow fell 58.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.87
0.06
−6.45%
Follow PHIO
Phio Pharmaceuticals Corp. (PHIO) P/E ratio
Phio Pharmaceuticals Corp. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2019 | 0.0× | — |
| Dec 2018 | 0.0× | — |
| Sep 2018 | 0.0× | — |
| Jun 2018 | 0.0× | — |
| 4 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KPRX Kiora Pharmaceuticals, Inc. compare | n/m |
| INTS Intensity Therapeutics Inc. compare | n/m |
| CLRB Cellectar Biosciences, Inc. compare | n/m |
| PTN Palatin Technologies, Inc. compare | n/m |
| PHIO Phio Pharmaceuticals Corp. | n/m |
| TPST Tempest Therapeutics, Inc. compare | n/m |
| BLRX BioLineRx Ltd. compare | n/m |
| GDTC CytoMed Therapeutics Limited compare | n/m |
| PASG Passage Bio, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)